Intestinal Research

Shujiro Yazumi

1 Article

The predictive variable regarding relapse in patients with ulcerative colitis after achieving endoscopic mucosal healing: Takuya Yoshino, Kohei Yamakawa, Satoshi Nishimura, Koutaro Watanabe, Shujiro Yazumi; Intest Res 2016;14(1):37-42. Published online January 26, 2016; DOI: https://doi.org/10.5217/ir.2016.14.1.37

<b>Background/Aims</b><br/>

Mucosal healing (MH) is a proposed therapeutic goal for patients with ulcerative colitis (UC). Whether MH is the final goal for UC, however, remains under debate. Therefore, to elucidate clinical variables predicting relapse after MH in UC could be useful for establishing further therapeutic strategy. The aim of this study is to evaluate the predictive variables for relapse in UC-patients after achieving MH.

Methods

From April 2010 to February 2015, 298 UC-patients treated at Kitano Hospital were retrospectively analyzed. MH was defined as Mayo endoscopic subscore of 0 or 1. The cumulative relapse free rate after achieving MH was evaluated. Predictive variables for relapse in UC-patients were assessed by Cox regression analysis.

Results

Of 298 UC-patients, 88 (29.5%) achieved MH. Of the 88 UC patients who achieved MH, 21 (23.9%) experienced UC-relapse. Based on Kaplan-Meier analysis, the cumulative relapse free rate at 1, 3, and 5 years after achieving MH was 87.9%, 70.2%, and 63.8%, respectively. The cumulative relapse free rate tended to be higher in the Mayo-0 group (76.9%) than in the Mayo-1 group (54.1%) at 5 years, although the difference was not statistically significant (P=0.313). Cox regression analysis indicated that the use of an immunomodulator was a predictive variable for relapse in UC-patients after achieving MH (P=0.035).

Conclusions

Our data demonstrated that the prognosis of UC patients after achieving endoscopic MH could be based on UC refractoriness requiring an immunomodulator.

Citations

Citations to this article as recorded by

Deep mucosal healing in ulcerative colitis: how deep is better?
Xin Jin, Yan You, Gechong Ruan, Weixun Zhou, Ji Li, Jingnan Li
Frontiers in Medicine.2024;[Epub] CrossRef
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis
Angelo Viscido, Marco Valvano, Gianpiero Stefanelli, Annalisa Capannolo, Chiara Castellini, Eugenia Onori, Antonio Ciccone, Filippo Vernia, Giovanni Latella
BMC Gastroenterology.2022;[Epub] CrossRef
Predicting Ulcerative Colitis Relapse in Clinical Remission With Fecal Immunochemical Occult Blood Test or Prostaglandin E-Major Urinary Metabolite
Natsuki Ishida, Tomoharu Matsuura, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Clinical and Translational Gastroenterology.2022; 13(7): e00501. CrossRef
Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse
Natsuki Ishida, Shunya Onoue, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
International Journal of Colorectal Disease.2021; 36(12): 2661. CrossRef
Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials
Toshifumi Hibi, Makoto Naganuma, Eisei Oda, Yoji Yamada, Yoshitomo Chujoh, Ryoichi Yoshihara, Mamoru Watanabe
Intestinal Research.2020; 18(1): 56. CrossRef
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis
Hyuk Yoon, Sushrut Jangi, Parambir S. Dulai, Brigid S. Boland, Larry J. Prokop, Vipul Jairath, Brian G. Feagan, William J. Sandborn, Siddharth Singh
Gastroenterology.2020; 159(4): 1262. CrossRef
Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam
Makoto Naganuma, Fumihito Hirai, Kiyonori Kobayashi, Kenji Watanabe, Ken Takeuchi, Nobuo Aoyama, Hiroshi Nozawa, Satoshi Motoya, Toshihide Ohmori, Akio Harada, Yushi Nagai, Takayuki Abe, Yoji Yamada, Katsutoshi Inagaki, Naoki Shimizu, Takanori Kanai, Mamo
PLOS ONE.2019; 14(8): e0220413. CrossRef
Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing
Takayuki Yamamoto, Takahiro Shimoyama, Satoru Umegae, Koichi Matsumoto
Clinical and Translational Gastroenterology.2018; 9(3): e136. CrossRef
European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska, Edouard Louis
Journal of Crohn's and Colitis.2018; 12(1): 17. CrossRef
Evaluation of the Potential Antioxidant Role of High-Density Lipoprotein-Cholesterol (HDL-C) in Patients with Ulcerative Colitis
Mostafa Vaghari Tabari, Soheila Moein, Durdi Qujeq, Mehrdad Kashifard, Javaad Shokri Shirvani, Karimollah Hajian Tilaki, Gholamreza Farshidfar
Annals of Colorectal Research.2017;[Epub] CrossRef

4,839 View
47 Download
9 Web of Science
10 Crossref

Author index